DEPARTMENT OF HEALTH & HUMAN SERVICES



MAR - 2 2000

Food and Drug Administration 2098 Gaither Road Rockville MD 20850

Ms. Melissa M. Traylor, RAC Director of Technical Services Regulatory Affairs Hardy Diagnostics 1430 West McCoy Lane Santa Maria, California 93455

Re: K000181

Trade Name: HardyDisk™ Carbenicillin 100mcg

Regulatory Class: II Product Code: JTN Dated: January 20, 2000

Received: January 20, 2000

Dear Ms. Traylor:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".

Sincerely yours,

Steven I. Gutman, M.D., M.B.A.

Director

Division of Clinical Laboratory Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Steven Butman

Enclosure



Email: Salen@Hardydiagnostics.co.ti Website: Hardydiagnostics.co.ti

> Santa Maria, California 1430 Wrist McCoy Laine Santa Adaria, CA 934: S Tel: [205] 315 27: 4 Fax [205] 346-27:00

> > Salt Lake City, Utah 254 W. Cultage Me. 5. My. 117 840 M 10: \$200) 995 42 M Fac. \$1011 502-32 4

Phoenix, Arizona 535 W. fron Ave., 4105 Mesa, A7 85216 Ter (100) 995 94.76 Can. (1002) 404 9036

Indications for Use Statement-HardyDisktm Carbenicillin, 100mcg

HardyDisk^{an} Antimicrobial Sensitivity Disks are used for semi-quantitative in vitro susceptibility testing by the agar diffusion test procedure (Kirby-Bauer) of rapidly growing and certain fastidious bacterial pathogens. Standardized methods for agar diffusion testing have been described for many organisms. Carbenicillin is indicated for in vitro activity against urinary pathogens including the Enterobacteriaciae and *Pseudomonas* spp., including *Pseudomonas* ueruginosu.

<end></end>				
Concurrence of CDRH	-ODE		•	
	Woo	del	whoes	
	(Division S	ign-Off)	mtom: Dordosa	
		nber KOC	ratory Devices O S	

Prescription Use (per 21 CFR 801.109)

OR

Over-the Counter-Use _____(Optional format 1-2-96)